A Phase 2 interventional study of Setmelanotide in Hypothalamic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 6 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Sexual Infantilism with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Sexual Infantilism · United States.
Among the 14 studies in Sexual Infantilism with a site in United States, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 5th registered.
23 studies on the registry are indexed under Sexual Infantilism; 5 are open to participants now.
Browse Sexual Infantilism studies →3 of the 14 studies in Sexual Infantilism with a site in United States are open now. Recruiting first, the newest first:
Rhythm Pharmaceuticals, Inc. · Sites in United States, United Kingdom
Ages 4+
Grace Kim · Sites in United States
Ages 18–26
Rhythm Pharmaceuticals, Inc. · Sites in United States, United Kingdom
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Sexual Infantilism studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 6 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 4 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 30 across 20 interventional studies indexed under Sexual Infantilism.
Median enrollment 27 across the 14 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 7 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Rhythm Pharmaceuticals, Inc. has 7 studies filed under Sexual Infantilism — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Infantilism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06760546Phase 3Rhythm Pharmaceuticals, Inc.A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | 2027-03-13 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Sexual Infantilism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be eligible for study participation:
Participant has documented evidence of HO, including:
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible for study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.
Drug: Setmelanotide
Setmelanotide for SC injection
Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline to 16 weeks
Composite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment
For participants aged ≥6 to \<18 years, a participant's BMI Z-score was considered for the analysis; for participants ≥18 years, a participant's body weight (kg) was considered for the analysis. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline to Week 16
Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline to 16 weeks
Percentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment
Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline to Week 16
Change From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment
Waist circumference was measured after participants had fasted for at least 8 hours and at approximately the same time at each visit. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 16
Change From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment
Daily Hunger Questionnaire for participants \<12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a pictorial (smiley face) version of the Likert rating scale with scores from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible. Responses were recorded in the electronic diary. Each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged to calculate a total score ranging from 0 (not hungry at all) to 4 (hungriest possible) with higher score indicating more hunger. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.
Time frame: Baseline, Week 16
Change From Baseline in Daily Hunger Questionnaire Scores in Participants Aged ≥12 Years After 16 Weeks of Setmelanotide Treatment
Daily Hunger Questionnaire for participants ≥12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible. The responses to the Daily Hunger Questionnaire were recorded in the electronic diary. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.
Time frame: Baseline, Week 16
Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged < 12 Years
Parents or caregivers of participants \<12 years old answered the Caregiver Reported Global Hunger Question for participants who were \<12 years old. The following question was asked: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; and Extremely hungry. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 16
Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged ≥12 Years
Global Hunger Questionnaire for participants ≥12 years of age. The following question was asked: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; and Severe hunger. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 16
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence or clinically significant worsening of an existing condition associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.
Time frame: From first dose of study drug up to Day 141
| Milestone | Setmelanotide |
|---|---|
| Started | 18 |
| Completed | 16 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage of participants | Setmelanotide |
|---|---|
| Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment | 88.9 (69.0 to 98.0) |
For participants aged ≥6 to \<18 years, a participant's BMI Z-score was considered for the analysis; for participants ≥18 years, a participant's body weight (kg) was considered for the analysis. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage of participants | Setmelanotide |
|---|---|
| Composite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment | 88.9 (69.0 to 98.0) |
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage of participants | Setmelanotide |
|---|---|
| Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment | 92.3 (68.4 to 99.6) |
Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage of participants | Setmelanotide |
|---|---|
| Percentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment | 80.0 (34.3 to 99.0) |
Waist circumference was measured after participants had fasted for at least 8 hours and at approximately the same time at each visit. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| cm | Setmelanotide |
|---|---|
| Change From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment | -10.275 ± 4.2272 |
Daily Hunger Questionnaire for participants \<12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a pictorial (smiley face) version of the Likert rating scale with scores from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible. Responses were recorded in the electronic diary. Each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged to calculate a total score ranging from 0 (not hungry at all) to 4 (hungriest possible) with higher score indicating more hunger. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.
| units on a scale | Setmelanotide |
|---|---|
| Change From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment | -1.490 ± 1.2126 |
Daily Hunger Questionnaire for participants ≥12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible. The responses to the Daily Hunger Questionnaire were recorded in the electronic diary. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.
| units on a scale | Setmelanotide |
|---|---|
| Most hunger | -2.922 ± 2.2851 |
| Average hunger | -3.122 ± 1.9999 |
| Morning hunger | -2.717 ± 1.9393 |
Parents or caregivers of participants \<12 years old answered the Caregiver Reported Global Hunger Question for participants who were \<12 years old. The following question was asked: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; and Extremely hungry. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| Participants | Setmelanotide |
|---|---|
| Not hungry at all (Baseline) - Not hungry at all (Week 16) | 0 |
| A little hungry (Baseline) - Not hungry at all (week 16) | 0 |
| Moderately hungry (Baseline) - Not hungry at all (Week 16) | 0 |
| Extremely hungry (Baseline) - Not hungry at all (Week 16) | 2 |
| Not hungry at all (Baseline) - A little hungry (Week 16) | 0 |
| A little hungry (Baseline) - A little hungry (Week 16) | 0 |
| Moderately hungry (Baseline) - A little hungry (Week 16) | 1 |
| Extremely hungry (Baseline) - A little hungry (Week 16) | 2 |
| Not hungry at all (Baseline) - Moderately hungry (Week 16) | 0 |
| A little hungry (Baseline) - Moderately hungry (Week 16) | 0 |
| Moderately hungry (Baseline) - Moderately hungry (Week 16) | 0 |
| Extremely hungry (Baseline) - Moderately hungry (Week 16) | 0 |
| Not hungry at all (Baseline) - Extremely hungry (Week 16) | 0 |
| A little hungry (Baseline) - Extremely hungry (Week 16) | 0 |
| Moderately hungry (Baseline) - Extremely hungry (Week 16) | 0 |
| Extremely hungry (Baseline) - Extremely hungry (Week 16) | 0 |
Global Hunger Questionnaire for participants ≥12 years of age. The following question was asked: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; and Severe hunger. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| Participants | Setmelanotide |
|---|---|
| No hunger (Baseline) - No hunger (Week 16) | 0 |
| Mild hunger (Baseline) - No hunger (Week 16) | 1 |
| Moderate hunger (Baseline) - No hunger (Week 16) | 3 |
| Severe hunger (Baseline) - No hunger (Week 16) | 0 |
| No hunger (Baseline) - Mild hunger (Week 16) | 1 |
| Mild hunger (Baseline) - Mild hunger (Week 16) | 0 |
| Moderate hunger (Baseline) - Mild hunger (Week 16) | 3 |
| Severe hunger (Baseline) - Mild hunger (Week 16) | 2 |
| No hunger (Baseline) - Moderate hunger (Week 16) | 0 |
| Mild hunger (Baseline) - Moderate hunger (Week 16) | 0 |
| Moderate hunger (Baseline) - Moderate hunger (Week 16) | 1 |
| Severe hunger (Baseline) - Moderate hunger (Week 16) | 0 |
| No hunger (Baseline) - Severe hunger (Week 16) | 0 |
| Mild hunger (Baseline) - Severe hunger (Week 16) | 0 |
| Moderate hunger (Baseline) - Severe hunger (Week 16) | 0 |
| Severe hunger (Baseline) - Severe hunger (Week 16) | 0 |
An AE was defined as any untoward medical occurrence or clinically significant worsening of an existing condition associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.
| Participants | Setmelanotide |
|---|---|
| Number of Participants With Adverse Events (AEs) | 18 |
Collected over From first dose of study drug up to Day 141. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Setmelanotide | 0/18 (0%) | 1/18 (5.6%) | 18/18 (100%) |
| Event | Setmelanotide |
|---|---|
| Clostridium difficile colitisInfections and infestations | 1/18 |
| Event | Setmelanotide |
|---|---|
| NauseaGastrointestinal disorders | 11/18 |
| VomitingGastrointestinal disorders | 6/18 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 6/18 |
| Erection increasedReproductive system and breast disorders | 3/11 |
| DiarrhoeaGastrointestinal disorders | 4/18 |
| COVID-19Infections and infestations | 4/18 |
| FatigueGeneral disorders | 3/18 |
| Injection site painGeneral disorders | 3/18 |
| Abdominal painGastrointestinal disorders | 3/18 |
| Injection site pruritusGeneral disorders | 2/18 |
The Full Analysis Set included all participants who received at least 1 dose of setmelanotide and had baseline data.
| Age, Continuous(years) | Setmelanotide |
|---|---|
| Mean | 15.0 ± 5.30 |
| Sex: Female, Male(Participants) | Setmelanotide |
|---|---|
| Female | 7 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Setmelanotide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 3 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Body Mass Index (BMI)(kilograms/square meter (kg/m^2)) | Setmelanotide |
|---|---|
| Mean | 37.95 ± 6.532 |
| Body Weight(kilograms (kg)) | Setmelanotide |
|---|---|
| Mean | 102.76 ± 30.120 |
| BMI Z-Score(z-score) | Setmelanotide |
|---|---|
| Mean | 3.935 ± 0.9080 |
| Waist Circumference(centimeters (cm)) | Setmelanotide |
|---|---|
| Mean | 114.07 ± 16.354 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Jun 2022, 12 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →